Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
Avectas Limited has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 5 distinct examiners across 3 distinct art units, indicating broad examiner distribution with multiple matters sharing art-unit settings. HENKEL, DANIELLE B is the busiest examiner, with 1 pending matter.
The assignment pattern supports a coordinated portfolio record combined with examiner-specific prosecution tactics. Counsel should compare objections within each art unit, then evaluate whether differences arise from examiner practice or from the claims and disclosures in the individual files. The matter before HENKEL, DANIELLE B is the identified examiner focus, but the distribution means that no single response strategy can be assumed to govern every pending matter.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 1 (20%) |
| §112 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HENKEL, DANIELLE B | 1 | 56.4% | +23.4% |
| MCKILLOP, JOHN CHARLES | 1 | 59.6% | +42.7% |
| LEVIN, JOEL D | 1 | 58.0% | +33.8% |
| WESTON, ALYSSA G | 1 | 59.2% | +50.7% |
| BOWERS, NATHAN ANDREW | 1 | 59.7% | +31.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18272699 | SEQUENTIAL DELIVERY OF RNPS TO IMMUNE CELLS | MCKILLOP, JOHN CHARLES | 22d overdue |
| 18760260 | VECTOR-FREE INTRACELLULAR DELIVERY BY REVERSIBLE PERMEABILISATION | HENKEL, DANIELLE B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18272699 | SEQUENTIAL DELIVERY OF RNPS TO IMMUNE CELLS | MCKILLOP, JOHN CHARLES | 22d overdue |
| 16841093 | DELIVERY ACROSS CELL PLASMA MEMBRANES | BOWERS, NATHAN ANDREW | 11d overdue |
| 17012748 | ENGINEERING OF IMMUNE CELLS FOR EX VIVO CELL THERAPY APPLICATIONS | WESTON, ALYSSA G | 15d |
| 18760260 | VECTOR-FREE INTRACELLULAR DELIVERY BY REVERSIBLE PERMEABILISATION | HENKEL, DANIELLE B | — |
| 17615081 | METHODS OF VIRAL DELIVERY TO A POPULATION OF CELLS | LEVIN, JOEL D | — |
| Art Unit | Apps |
|---|---|
| 1633 | 2 |
| 1637 | 1 |
| 1799 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18760260 | VECTOR-FREE INTRACELLULAR DELIVERY BY REVERSIBLE PERMEABILISATION | HENKEL, DANIELLE B | — | §102§103Other | Non-Final OA | — | Pending | Jul 01, 2024 |
| 18272699 | SEQUENTIAL DELIVERY OF RNPS TO IMMUNE CELLS | MCKILLOP, JOHN CHARLES | 1637 | §101§102§112Other | Final Rejection | 22d overdue | Pending | Jul 17, 2023 |
| 17615081 | METHODS OF VIRAL DELIVERY TO A POPULATION OF CELLS | LEVIN, JOEL D | 1633 | §103 | Non-Final OA | — | Pending | Nov 29, 2021 |
| 17012748 | ENGINEERING OF IMMUNE CELLS FOR EX VIVO CELL THERAPY APPLICATIONS | WESTON, ALYSSA G | 1633 | §112 | Final Rejection | 15d | Pending | Sep 04, 2020 |
| 16841093 | DELIVERY ACROSS CELL PLASMA MEMBRANES | BOWERS, NATHAN ANDREW | 1799 | §103DP | Non-Final OA | 11d overdue | Pending | Apr 06, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAvectas Limited has 5 pending office actions as of November 2026, spread across 3 art units and 5 examiners.
Danielle B Henkel has the most, with 1 of Avectas Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.